MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12185-024-03896-9

Медицинская библиотека · International journal of hematology · 2024

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis.

Yamakawa Kazuma, Okamoto Kohji, Seki Yoshinobu, Ikezoe Takayuki, Ito Takashi, Iba Toshiaki, Gando Satoshi, Ushio Noritaka, Totoki Takaaki, Wada Takeshi, Asakura Hidesaku, Ishikura Hiroyasu, Uchiba Mitsuhiro, Uchiyama Toshimasa, Kawasaki Kaoru, Kawano Noriaki, Kushimoto Shigeki, Koga Shin, Sakamoto Yuichiro, Tamura Toshihisa, Nishio Kenji, Hayakawa Mineji, Matsumoto Takeshi, Madoiwa Seiji, Mayumi Toshihiko, Yamada Shinya, Wada Hideo, Committee of the Clinical Practice Guidelines for Management of Disseminated Intravascular Coagulation 2024, the Japanese Society on Thrombosis and Hemostasis

СтатьяКлинические рекомендацииОбзорПеревод в очереди

Аннотация

The Japanese Society on Thrombosis and Hemostasis (JSTH) published the first-ever disseminated intravascular coagulation (DIC) guidelines in 2009. Fifteen years later, the JSTH developed new guidelines covering DIC associated with various underlying conditions. These guidelines were developed in accordance with the GRADE system to determine the strength of the recommendations and certainty of the evidence. This article was drafted as Part 1 of an overall DIC guideline covering various underlying conditions, with sepsis as the subject. In this section, seven key clinical issues (questions) are set. Question 1, regarding DIC diagnosis, introduces several diagnostic criteria, such as the JAAM-2, ISTH overt, SIC, and JSTH DIC criteria and recommends choosing the appropriate diagnostic criteria for DIC based on an understanding of their diagnostic properties. For pharmacotherapy in DIC patients with sepsis, we recommend the administration of antithrombin (Question 2) and recombinant thrombomodulin (Question 3) (both GRADE 1B). However, we do not make a clear recommendation regarding the administration of heparin (Question 6) and serine protease inhibitors (Question 7) because of the lack of evidence. Combination therapy, order of administration, and other administration methods for antithrombin and recombinant thrombomodulin are proposed as important future research questions (Questions 4 and 5).

Для цитирования: Yamakawa Kazuma, Okamoto Kohji, Seki Yoshinobu, Ikezoe Takayuki, Ito Takashi, Iba Toshiaki, Gando Satoshi, Ushio Noritaka, Totoki Takaaki, Wada Takeshi, Asakura Hidesaku, Ishikura Hiroyasu, Uchiba Mitsuhiro, Uchiyama Toshimasa, Kawasaki Kaoru, Kawano Noriaki, Kushimoto Shigeki, Koga Shin, Sakamoto Yuichiro, Tamura Toshihisa, Nishio Kenji, Hayakawa Mineji, Matsumoto Takeshi, Madoiwa Seiji, Mayumi Toshihiko, Yamada Shinya, Wada Hideo, Committee of the Clinical Practice Guidelines for Management of Disseminated Intravascular Coagulation 2024, the Japanese Society on Thrombosis and Hemostasis. Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis.. International journal of hematology. 2024. DOI: 10.1007/s12185-024-03896-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.